|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
|
SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-PSMA-617 Radionuclide Therapy
|
| Thomas Hope, MD |
| Phillip Koo speaks with Thomas Hope about the Journal of Nuclear Medicine published consensus statement on the use of lutetium-177-PSMA-617 radionuclide therapy for prostate cancer. The statement aims to guide clinicians on patient selection and appropriate use, particularly in complex cases.
|
|
|
|
|
|
|
|
|
|
|
|
|
Lutetium-177 Therapy Yields Outstanding Response in Chemo-Naive Prostate Cancer Patient
|
|
Nasrin Ghesani, MD
|
| Nasrin Ghesani shares a case of a 71-year-old prostate cancer patient's significant recovery with lutetium-177 therapy. Initially diagnosed in 2012, the patient underwent numerous treatments including a radical prostatectomy and hormone therapies, before transitioning to lutetium PSMA-617 therapy in 2022. |
|
|
|
|
|
|
|
|
|
|
|
|
The Radiopharmaceutical Revolution: New Frontiers in Prostate Cancer Treatment
|
Oliver Sartor, MD
In this conversation, Oliver Sartor highlights the rapidly evolving landscape of radiopharmaceuticals for prostate cancer with Alicia Morgans. They discuss significant advances in the space and several ongoing trials that could change practice.
|
|
|
|
|
|
|
|
|
|
|
| PSMAfore: A Phase 3 Study To Compare 177Lu-PSMA-617 Treatment With a Change in Androgen Receptor Pathway Inhibitor in Taxane-Naïve Patients With Metastatic Castration-Resistant Prostate Cancer
|
| A. Oliver Sartor MD
|
| In this presentation, Oliver Sartor discusses the rationale and design of the PSMAfore trial, a phase 3 study designed to investigate the role of [177Lu]Lu-PSMA-617, a radioligand therapy, in patients with mCRPC who are taxane-naïve. This multicenter trial aims to determine the effect of [177Lu]Lu-PSMA-617 or a change in androgen receptor pathway inhibitors on radiographic progression-free survival in these patients and will involve 450 participants.
|
|
|
|
|
|
| Lutetium-PSMA Therapy
|
| Matthew Smith, MD, Ph.D.
|
| Matthew Smith discusses the role of prostate-specific membrane antigen (PSMA)-lutetium radionuclide therapy, including considerations regarding monotherapy, combination therapy, and patient selection. He emphasizes that 177Lu-PSMA-617 is now a treatment option for patients with heavily pretreated mCRPC with evidence of significantly improved survival. Baseline PSMA avidity appears to be predictive of the response to treatment and may help guide patient selection.
|
|
|
|
|
|
|
|
|
|
|
| Developing a Novel Patient-Reported Outcome Measure for Patients with Prostate Cancer Receiving Radionuclide Therapy: The FACT-RNT
|
| Lisa M. Gudenkauf, Ph.D.
|
| Lisa Gudenkauf presents the framework for the FACT-RNT, a novel patient-reported outcome measure for patients with prostate cancer receiving radionuclide therapy. The FACT-RNT (Functional Assessment of Cancer Therapy – Radionuclide Therapy) is an RNT-specific PROs measure for patients receiving RNTs, developed through a multi-disciplinary collaboration with patients, caregivers, clinicians, and international experts.
|
|
|
|
|
|
| Increased Utilization of Prostate-Specific Membrane Antigen (PSMA)-Targeted Radionuclide Therapy (PSMA-TRT) in African American (AA) Patients at an Academic Medical Center
|
| Joseph Earl Thomas, MD
|
Joseph Thomas presents his group’s study evaluating the increased utilization of prostate-specific membrane antigen-targeted radionuclide therapy (PSMA-TRT) in African American patients at their Academic Medical Center. These data suggest that outreach and increasing access to African American patients for novel prostate cancer treatment such as PSMA-TRT may be causally associated with increased numbers of underrepresented patients enrolling on clinical trials and gaining access to novel medical therapeutic regimens.
|
|
|
|
|
|
| Personalized PSMA-Directed Molecular RT with Identification of Favorable Genomic and Post-Therapeutic Radiomic Parameters: A Real-World Experience Post-FDA-Approval of Lu-177 PSMA-617 from a Single Comprehensive U.S. Theranostic Center
|
| Harshad Kulkarni, MD
|
| Harshad Kulkarni discusses personalized PSMA-directed molecular radiotherapy with the identification of favorable genomic and post-therapeutic radiomic parameters. With the publication of the VISION trial, the FDA and EMA subsequently approved the use of Lu-177 PSMA-617 in the third-line setting of metastatic castration-resistant prostate cancer treatment. |
|
|
|
|
|
|
